Dr. Sonia Macieiewski (R) and Dr. Nita Patel, Director of Antibody discovery and Vaccine development, look at a sample of a breathing infection at Novavax labs in Rockville, Maryland on March 20, 2020, one of the labs establishing a vaccine for the coronavirus, COVID-19. The vaccine produced neutralizing antibodies, which researchers believe are essential to build immunity to the infection, and killer T-cells, the business stated. Novavax is among a number of companies racing to establish a vaccine to fight the virus, which has actually contaminated more than 20.9 million people around the world and eliminated at least 760,000 as of Friday, according to data compiled by Johns Hopkins University.

Dr. Sonia Macieiewski (R) and Dr. Nita Patel, Director of Antibody discovery and Vaccine advancement, look at a sample of a respiratory virus at Novavax labs in Rockville, Maryland on March 20, 2020, one of the laboratories establishing a vaccine for the coronavirus, COVID-19. The vaccine produced reducing the effects of antibodies, which researchers think are essential to develop immunity to the infection, and killer T-cells, the business stated. Novavax is among several companies racing to establish a vaccine to fight the infection, which has actually infected more than 20.9 million people worldwide and killed at least 760,000 as of Friday, according to data assembled by Johns Hopkins University.

LEAVE A REPLY

Please enter your comment!
Please enter your name here